Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
HUGE | CSE | CAD | Delayed | |
HUGE | NASDAQ | USD | Real-time | |
HUGE | CBOE Canada | CAD | Real-time | |
0K9 | Frankfurt | EUR | Delayed |
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Anthony John Durkacz | 48 | 2018 | Founder & Executive Co-Chairman |
Zeeshan Saeed | 54 | 2021 | Founder, CEO, President & Executive Co-Chairman |
Daniele Piomelli | - | 2022 | Member of Research & Clinical Advisory Board |
Jason D. Sawyer | - | 2022 | Member of Advisory Board |
Navdeep Jaikaria | 61 | - | Member of Advisory Board |
Lakshmi P. Kotra | 53 | 2021 | CEO of Lucid & Director |
Adnan Bashir | 54 | 2021 | Independent Director |
Shannon Dunn | - | 2021 | Member of Research & Clinical Advisory Board |
Hance Clarke | - | 2021 | Member of Research & Clinical Advisory Board |
Eleanor N. Fish | - | 2021 | Member of Research & Clinical Advisory Board |
Joga Gobburu | - | 2021 | Member of Regulatory Advisory Board |
Mary Melnyk | - | 2021 | Member of Regulatory Advisory Board |
Peter K. Stys | - | 2021 | Member of Research & Clinical Advisory Board |
Eric William Hoskins | 62 | 2023 | Independent Director |
Kevin Harrington | 67 | 2023 | Member of Advisory Board |
Kwok Chow | - | 2022 | Member of the Regulatory Advisory Board |
Michael Zapolin | 57 | 2023 | Independent Director |
Gerald V. David | 72 | 2023 | Member of Advisory Board |
David G. P. Allan | 82 | 2022 | Member of Advisory Board |
Alexander Bar | - | 2023 | Member of Advisory Board |
Ravinder Kumar | - | 2022 | Member of Advisory Board |
Albert H.C. Wong | - | 2021 | Member of Research & Clinical Advisory Board |
Sanjiv Chopra | 74 | 2024 | Independent Director |
John McGraw | - | 2022 | Member of Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review